-+ 0.00%
-+ 0.00%
-+ 0.00%

ImmunoPrecise's LENSai Achieves Ability To Accurately Predict Binding On 17 Previously Unseen Antibody-Antigen Complexes, Achieving Near-Crystallography Precision Without Prior Training Data

Benzinga·07/03/2025 12:21:22
Listen to the news

New benchmark confirms LENSai's ability to accurately predict binding on 17 previously unseen antibody-antigen complexes, achieving near-crystallography precision without prior training data.

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) ("IPA" or the "Company"), an AI-powered biotherapeutics company, today announced a new validation study supporting the generalizability of its proprietary epitope mapping platform, LENSai, powered by IPA's patented HYFT® technology. The newly released benchmark shows that the platform consistently delivers high predictive performance, even on complexes not used during training.